跳至主要内容
临床试验/NCT01045668
NCT01045668已完成3 期

Comparison of the Effect of Ablation of the Clinically Presenting Ventricular Tachycardia (VT) Only Versus the Addition of Substrate Ablation Based on Scar Mapping; on the Long Term Success Rate of VT Ablation

Texas Cardiac Arrhythmia Research Foundation1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2010年1月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
120
试验地点
1
主要终点
Recurrence of any sustained VT in the post-ablation period as demonstrated by electronic documentation Procedural complications associated with prolonged use of radiofrequency (RF) energy such as perforation, cardiac tamponade

研究概览

简要总结

This study aims to assess whether a combined technique of substrate ablation and ablation of the clinically presenting VT at the site of early activation is superior to ablation of the clinically presenting VT alone, in enhancing long-term success of VT ablation.

详细描述

Background: VT is found mostly in patients with structural heart disease. It is classified using morphological criteria (monomorphic or polymorphic), duration of arrhythmia (sustained or non-sustained) or the mechanism of arrhythmia formation (re-entry, increased automation or triggered activity). The therapeutic approach and prognostic estimates of these different types of VT depend to a great degree on the mechanistic basis of the disease as well as the extent of myocardial damage and success of the therapy is measured by the absence of recurrence.

Myocardial infarction with subsequent induction of VT is observed as a consequence of coronary artery disease (CAD). The infarct regions that are morphologically and electrically diseased can be arrhythmogenic and may form the substrate for macro-reentrant VT.

Although antiarrhythmic drugs remain the primary form of therapy for VT, non-pharmacologic techniques like implantable cardioverter-defibrillator (ICD) and catheter ablation (CA) are becoming increasingly popular because of advancement in technology as well as an increase in desire among patients to eliminate the arrhythmia with ablation rather than suppressing it with drugs. ICDs and CA effectively terminate VT on a short-term basis; but multiple morphologies, hemodynamic instability and non-inducibility limit the long-term success rate of CA. The 'substrate mapping' approach defines areas of ventricular scar which can be potential VT sources. Several studies on small groups of patients have shown that successful ablation of VT substrates either reduces the recurrence of VT to 19- 50% or reduces the frequency of recurrence as well as the requirement of anti-arrhythmic drugs (AADs).

Study design:

This study is a multicenter, randomized, open label, parallel-arm clinical trial. A total of 120 post-myocardial infarction patients will be randomized at a 1:1 ratio into 2 groups:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Previous Myocardial infarction
  • •Symptomatic, drug-refractory and haemodynamically stable VT following CAD
  • •Undergoing a VT ablation
  • •Implanted ICD

排除标准

  • •Documented valvular heart disease
  • •Acute myocardial infarction within the preceding 1 month
  • •Unstable angina
  • •Prolonged QT interval
  • •Patients with hemorrhagic or thrombophilic disorders
  • •Documented intra-atrial thrombus, tumor or other conditions which prevent easy catheter introduction

研究组 & 干预措施

Clinical VT ablation

Active Comparator

干预措施: Radiofrequency Catheter Ablation (RFCA) (Procedure)

clinical VT and substrate ablation

Active Comparator

干预措施: Radiofrequency Catheter Ablation (RFCA) (Procedure)

结局指标

主要结局

Recurrence of any sustained VT in the post-ablation period as demonstrated by electronic documentation Procedural complications associated with prolonged use of radiofrequency (RF) energy such as perforation, cardiac tamponade

时间窗: 48 hours

次要结局

  • Severe clinical events (hospital admissions for a cardiac cause, syncopal attacks, number of episodes of VT storms, death) Number of ICD interventions(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrea Natale

Executive Medical Director

Texas Cardiac Arrhythmia Research Foundation

研究点 (1)

Loading locations...

相似试验